|Bid||6.83 x 4000|
|Ask||6.83 x 800|
|Day's Range||6.79 - 7.37|
|52 Week Range||6.14 - 40.40|
|Beta (3Y Monthly)||1.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Amazon launching a new pickup option called "Counter" with RiteAid. The service enables customers to pickup packages at RiteAid stores. Yahoo Finance's Melody Hahm joins Seana Smith.
Walgreens' stock is surging on better than expected quarterly earnings results. Yahoo Finance's Heidi Chung joins Seana Smith on 'The Ticker' to discuss potential headwinds the company could face moving forward.
Rite Aid announced a partnership with Amazon allowing shoppers to pick their orders up at more than 100 Rite Aid stores, but reported a quarterly earnings miss. Yahoo Finance's Dan Roberts, Akiko Fujita and Sibile Marcellus discuss.
Ford, Verizon, Amazon, Rite Aid, Google and Bayer are the companies to watch.
CVS Health (NYSE:CVS) can't catch a break. Neither can its shareholders. CVS stock is at roughly half the value it was at its mid-2015 peak. And it only recently came off its May multi-year lows. Good news about cancelled drug-rebate plans that would have cost it a fortune shoved shares higher earlier this month. Now, that move has largely come undone. The bears appear to remain in charge.Source: Shutterstock Nothing lasts forever though. While CVS Health stock may look and feel stuck in a downtrend, don't despair: what the company is building is very much the future of healthcare.The organization gave stakeholders of CVS stock another glimpse of that future this week.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Desperate MeasuresThe short version of a story most everyone knows: the state of the healthcare system in the U.S. is laughable. Its sheer size and complexity, coupled with misguided regulation, has made it unaffordable for all. * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip That's a key part of the reason strange-bedfellows Amazon (NASDAQ:AMZN), JPMorgan Chase (NYSE:JPM) and Berkshire Hathaway (NYSE:BRK.A, NYSE:BRK.B) made this announcement last year: they're forming their own healthcare company of sorts for their employees. Though not insurance per se, it was a means of offering low-cost clinical care in-house. Further, this move would also cull at least some of their healthcare and insurance expenses.However, it's hardly the only instance where such lines have crossed.Case in point: CVS rival Walgreens Boots Alliance (NASDAQ:WBA) has partnered with clinics to offer in-store (or near-store) primary care, as has CVS.Arguably, CVS took the boldest even if not the biggest step towards an industry shakeup last year. That was when the pharmacy giant announced its intent to merge with health insurer Aetna. The deal closed in late 2018.Responses were mixed. Concerned observers noted it was an opportunity for self-serving steering that crimps competition even if it doesn't kill it. Others lauded the idea, pointing out that with one less middleman, the industry could lower costs.Regardless, this is the new norm for the very same healthcare industry that collectively priced itself into the trouble it's now looking to escape.CVS Health carried the ball a bit further downfield this week, unveiling a home dialysis system that just began its required clinical trials. Disruption UnderwayIt wasn't a surprise, but it was a milestone nonetheless.CVS Health was and is a pharmacy, and now facilitates clinical/frontline care. Aetna is an insurer and can keep hospital and drug prices in check. However, neither arm has pushed its way onto biotech equipment turf until now.Last year's news of the planned project already put dialysis rivals into action. Davita (NYSE:DVA) as well as Fresenius Medical Care (NYSE:FMS) have both ramped up efforts to facilitate more at-home dialysis. Such moves saves patients from visits to their specialty clinics.That paradigm shift should also lower total costs for dialysis patients.Meanwhile, the Aetna/CVS deal has put the nation's traditional frontline players on notice. Ken Kaufman, managing director and chair of consulting firm Kaufman Hall, commented earlier that year that the once-unlikely pairing was "a shot across the bow of hospitals in America."In the same vein, the creation of Haven -- the name given to the entity co-created by JP Morgan, Amazon and Berkshire -- was a shot across the bow of pharmacies like CVS and insurers like Aetna.It's CVS, however, that's leading the charge of disruption, even if that means disrupting itself. CVS Stock Is Undervalued and OversoldCVS Health may be the face of a new era of integrated healthcare, but investors are clearly not buying it. Extending a pullback that began in 2015, 2017's initial efforts to team-up with Aetna along with uncertainty as to how the business might change under President Trump have ultimately worked against CVS Health stock.That concern largely has no merit though. Indeed, with Rite Aid (NYSE:RAD) on its heels and Walgreens not taking the same bold step CVS did to shape its own future rather than be shaped by it, investors have seemingly overlooked CVS Health's impressive past and compelling future. Click to EnlargeRevenue was growing and will continue to do so. The introduction of Aetna's business a couple of quarters ago had no bearing on the revenue trajectory. Analysts expect earnings per share of CVS stock to slide once this year. And then, it will likely move on to record-breaking levels for the newly combined companies. That's a victory in and of itself. Consider that the new-share issuance of CVS Health stock partly funded the acquisition.Notice the addition of Aetna will also stabilize CVS's otherwise wide seasonal swings in income.Perhaps the most bullish argument of all is the stock's forward-looking price-earnings ratio of 7.9. With or without challenges ahead, that's dirt cheap given the profit CVS Health could drive simply by coasting ahead. Looking Ahead for CVS Health StockThat being said, two key clues suggest the sentiment tide may have finally taken a turn for the better.One of them is the way CVS shares have repeatedly found a technical floor near $51.70. This is plotted with a yellow, dashed line on the chart. Bears have tested that floor three times since March, but it held up every time. It's a foundation the bulls can build on now that it's been established. Click to EnlargeThe other noteworthy nuance here is the amount of bullish volume that's kept CVS stock propped up. While February's pullback volume was significant, the same number of buyers (and perhaps more) have wanted to step back in.It's the first time we've seen this much technical support aided by this much buying interest.There's still work to be done, and there's still plenty of risk ahead. This week has been less than thrilling, with the buyers unwilling to follow through on last week's jolt. The bearish case is starting to crumble under the weight of the bullish case though. Its vertical and horizontal integrations appear to be working.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about him at his website jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading The post The Worst Appears to Be Over for CVS Stock appeared first on InvestorPlace.
Amazon.com Inc. Prime Day is not just a big day for retail sales at the e-commerce giant, it’s also serving as a major debut for Amazon’s one-day delivery promise for Prime members. Amazon (AMZN) announced in April that it was cutting its free two-day shipping offer in half for Prime members at a cost of $800 million in the second quarter. A quarter of the U.S. plans to purchase something during the Prime Day event, according to the latest data from YouGov, which surveyed 27,422 adults.
Rite Aid Corp. , the Rite Aid Foundation, and Google Maps have partnered to make it easier for users to find a medication disposal unit at a Rite Aid or a KidCents Safe Medication Disposal Unit at a local police station or enforcement agency. The Rite Aid Foundation launched the KidCents Safe Medication Disposal program in 2017 and it's now in 18 states. Rite Aid recently installed the last of 100 medication disposal units in a store in Ottawa, Ohio. Rite Aid also makes DisposeRX packets available, a biodegradable powder that, when mixed with water, dissolves prescriptions drugs. Rite Aid stock is down 5% in Monday trading and down nearly 41% for the year to date. Shares of Alphabet Inc. , Google Maps parent, are up almost 11% for the year so far. And the S&P 500 index has gained 20.2% for 2019 so far.
When it comes to CVS Health (NYSE:CVS), there's no shortage of reasons to steer clear of CVS stock. Pharmacies are getting hammered by lower reimbursement rates and higher costs. Health insurers -- recall that CVS acquired Aetna last year -- are struggling. CVS Health stock is down 16.3% this year.Source: Mike Mozart via FlickrBut wait, there's more: That Aetna deal may be reversed. Amazon.com (NASDAQ:AMZN) looms, fueled by its PillPack acquisition and its Haven health care joint venture, with partners JPMorgan (NYSE:JPM) and Berkshire Hathaway (NYSE:BRK.B).Those risks have led to an ugly chart for CVS Health stock. In March, CVS stock touched its lowest level in almost six years. Since then, the shares have traded mostly sideways, returning to those lows several times before a recent, modest, bounce.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut at the lows, CVS becomes an interesting contrarian pick. CVS stock is cheap - - and close to absurdly so. Some of the headwinds facing the company should reverse at some point. The legal uncertainty surrounding Aetna doesn't necessarily seem like bad news. And the threat of Amazon may be overblown, as it so often has been.That's not to say those risks aren't real. And with a huge debt load post-Aetna, CVS stock absolutely can fall further. Still, with support seemingly intact and the valuation pricing in those concerns, the risk-reward surrounding CVS Health stock looks attractive. CVS Health Stock Tanks … And So Do PeersPerhaps the biggest change surrounding CVS stock of late is that the pharmacy business model has moved from being perceived as a strength to seen as a weakness. Pharmacies long were considered defensive stocks; even in an economic downturn, consumers still needed their prescriptions. Indeed, CVS earnings rose over 12% in 2009 -- at the same time the U.S. was dealing with the worst of the Great Recession. (To be sure, CVS stock still tanked as investors sold pretty much every U.S. equity.) * The 7 Top Small-Cap Stocks Of 2019 It's not just CVS that's struggling. Shares of Walgreens (NASDAQ:WBA), too, touched a nearly six-year low in late May. Rite Aid (NYSE:RAD) stock has collapsed to the point that a reverse split was required.Three key factors are behind the industry's troubles.One, pharmacies are receiving lower reimbursement rates from insurers. As efforts to rein in costs cascade through the health care system, pharmacies are taking the brunt.Another factor is that generic drugs aren't coming as quickly as they have in the past -- and they aren't as cheap as they used to be. Without steady savings from generics to offset lower rates, margins in the pharmacy business have crumbled.Adjusted operating income in CVS' retail/long-term care (LTC) segment declined 19% in the first quarter. While the LTC business struggled, the pharmacy business was a big driver. Walgreens highlighted similar pressures in its recent fiscal third quarter report.And, finally, front-end sales remain weak. For CVS, front-end sales declined 2.6% in 2017 and 1.5% in 2016. A 0.5% increase in 2018 still suggests negative growth over the three-year period. Whether that weakness is coming from e-commerce competition, improved convenience stores from fuel sellers like Exxon Mobil (NYSE:XOM) and Chevron (NYSE:CVX), or other factors, isn't entirely clear yet. But here, too, Rite Aid and Walgreens are seeing similar trends. Amazon and PillpackEssentially, the pharmacy business looks tough right now. And it may get tougher. Amazon long has been considered a potential entrant in the pharmacy space. That speculation only intensified after the e-commerce giant acquired PillPack last year.As Luke Lango detailed in February, Amazon appears to be a real threat to CVS Health -- and to CVS Health stock. And that's not just a matter of displacing in-store prescription sales through a mail-order model.Rather, it appears increasingly likely that Amazon is considering disrupting the pharmacy benefit manager (PBM) model. CVS is one of the three titans in PBM, through the Caremark business that it acquired back in 2007. Cigna (NYSE:CI) recently acquired Express Scripts, another big player, while UnitedHealth Group (NYSE:UNH) has substantial share through its OptumRx unit.As Barron's noted, about 70% of earnings, even after the Aetna deal, come from the retail pharmacy and the Caremark PBM. Investors fear those profits are at significant risk. With health insurers not exactly setting the world on fire -- a basket of the largest health insurance stocks would be roughly flat over the last year -- it's not hard to see why CVS is trading at such paltry earnings multiples. Is The Aetna Deal At Risk?With all those risks, the last thing shareholders needed was another one. But now it appears the already-closed Aetna deal might be at risk.As InvestorPlace contributor Dana Blankenhorn detailed last month, a federal judge is reviewing the merger, and in theory could force the two companies to separate. Case law here is murky, and the odds that the court actually reverses an already-closed deal seem slim. But it is a possibility -- and one that could be close to disastrous for CVS Health.After all, it's not entirely clear how such a separation could even work. What happens to the $48 billion in cash that CVS paid to Aetna shareholders? Will they send bills? Would Aetna stock be re-listed? The practical considerations alone would seem to dissuade Judge Richard Leon from actually separating the two companies, were he so inclined. * 7 Retail Stocks to Buy That Are Down in 2019 Still, the risk is out there. And as one of many, investors have responded accordingly. But assuming a somewhat orderly split, even a reversal of the merger might not be bad news for CVS stock. Investors didn't really like the deal to begin with: CVS stock now is down by about 30% since it was announced. Would a reversal be greeted by more selling -- or a relief rally? The Case for CVS Health StockAgain, these worries can't be ignored. But there's also an appealing contrarian case for CVS Health stock.First, CVS stock is cheap. Ridiculously cheap as 2019 EPS guidance of $6.75-$6.90 was reaffirmed at the company's Investor Day last month. Even the low end of the range suggests CVS trades at 8.2x earnings.Meanwhile, at the same event, CVS guided for steady growth going forward: $7+ in 2020 EPS, followed by mid-single-digit growth in 2021 and 10%+ increases afterward. CVS could target EPS nearing $10 per share by 2024; assuming even a still-soft 12x multiple, the stock would more than double in five years even before a current 3.6% dividend yield.Debt funding the Aetna deal (for now) does help that multiple. But even on an EV/EBITDA basis, which includes the company's borrowings, a 7x+ multiple is the company's lowest in years. By any measure, CVS is priced for earnings declines - while management insists that growth is ahead.And management could be right. CVS is moving toward a diversified health care offering, between insurance, a PBM, and in-store care through its HealthHUBs. Reimbursement rate pressures may ease at some point. Front-end sales already are being de-emphasized, as the HealthHUBs replace space currently allocated to slower sellers.Contrarian investing always is tricky -- particularly when a company has the debt and the headwinds that CVS has. A stock like that never truly gets "too cheap". But CVS is cheap and management believes it will be a beneficiary of the transformation of U.S. health care. If management is even close to right, CVS stock will rally at some point.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Best Stocks for 2019: A Volatile First Half * 7 Simple Ways for Young Investors to Invest Their First $1,000 * 6 Stocks to Buy Based on Insider Buying The post If Everything is Going Wrong for CVS Health Stock, is That a Buy Signal? appeared first on InvestorPlace.
One thing that distinguishes Amazon.com (NASDAQ:AMZN) from its Chinese doppelganger, Alibaba Group Holding (NASDAQ:BABA), is the latter's larger retail footprint.Source: Amazon While Alibaba has been buying supermarkets and shopping malls, and stuffing them with branded technology and services, Amazon has only bought Whole Foods, an upscale food store that still operates with a degree of autonomy.The infrastructure that Amazon is most devoted to isn't in retailing, but delivery. Some see that changing. Kohl's (NYSE:KSS) is making all its stores into Amazon drop-off locations. Rite Aid (NYSE:RAD) has launched a pilot making its stores Amazon package pick-up locations.InvestorPlace - Stock Market News, Stock Advice & Trading TipsRite Aid hopes people picking up Amazon packages will stay to get prescriptions filled. Kohl's hopes people dropping off packages for Amazon will stay to try on some clothes. But what's in this for Amazon? Amazon is InfrastructureAmazon has hurdles in the way of getting a greater share of the American wallet and making more than a retailer's profit on that share. * The 7 Top Small-Cap Stocks Of 2019 Thieves steal packages from stoops. Many of my neighbors have had this happen. Returns are a hassle. I have a package of stand mixer beaters on my desk I need to send back … and it's gathering dust.Amazon's fulfillment system lets retailers absorb its inventory risk. The beaters on my desk come from a Florida retailer called Goodman's.But Amazon's retail operations aren't where it makes its money. They're a source of cash flow used to invest in cloud computing centers, warehouses and delivery vehicles. The computers make money. The other infrastructure doesn't. This is partly because the computers run without people. The warehouses don't. People like to be fed.Analysts assuming Amazon will now buy Rite Aid, or Kohl's, are missing the point. Amazon doesn't see itself as a retail company. It never did. Amazon is, was, and always will be an infrastructure company.Warehouses are infrastructure. Delivery vehicles are infrastructure. Clouds are infrastructure. Broadband, too, is infrastructure. If Amazon can build out a constellation of 3,256 satellites and cover the world in broadband, as it's proposing, it can offer that infrastructure to competitors and make a profit from them.Amazon doesn't have to own the merchandise it sells you, although policing merchants is increasingly expensive. The aim is to make itself essential, not in the way Walmart (NYSE:WMT) is, more in the way FedEx (NYSE:FDX) is.Retail mark-ups look fat but even the best-run retailers only bring about 3% of that volume to the bottom line … and that's in a good year. That's why Kroger (NYSE:KR) is worth just $17 billion, less than one-tenth last year's sales of $121 billion. * 7 Retail Stocks to Buy That Are Down in 2019 Infrastructure profits are far more certain. If Amazon can drive the cost of its infrastructure below that of rivals, it can replicate the success its Amazon Web Services has had. During the first quarter of this year AWS had operating income of $1.4 billion on revenue of $5.44 billion. The rest of the company made less than $1 billion on sales of $45 billion. Bottom Line on Amazon StockFor Amazon, retailing is a means to an end.The end is the margin Amazon makes from its infrastructure. By cutting the cost of getting merchandise from factories to your front door, and by running its own retailing at break-even, Amazon hopes to become America's middleman.Amazon next reports earnings on July 25, with net income of $5.28 per share of AMZN stock expected on revenue of $62.51 billion. That's a year-over-year growth rate of 18% on the top line, but barely more than the $5.15 per share earned a year ago.The point is that for years investors focused on Amazon's growth rate and cash flow. The Amazon stock investment thesis from here on will be watching its middleman margins grow.Dana Blankenhorn is a financial and technology journalist. He is the author of a new environmental story, Bridget O'Flynn and the Bear, available now at the Amazon Kindle store. Write him at email@example.com or follow him on Twitter at @danablankenhorn. As of this writing he owned shares in AMZN, BABA and KR. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Best Stocks for 2019: A Volatile First Half * 7 Simple Ways for Young Investors to Invest Their First $1,000 * 6 Stocks to Buy Based on Insider Buying The post Latest Brick-and-Mortar Pacts Make Amazon Americaas Middleman appeared first on InvestorPlace.
Rite Aid (RAD) expands the availability of its Thrifty Ice Cream brand in select stores in Delaware, New York, Maryland, New Jersey and Pennsylvania.
Amazon has partnered with Rite Aid to provide staffed package pick-up services at 100 of the pharmacy’s locations across the country with plans to roll out the program to 1,500 stores by the end of the year. Amazon (Nasdaq: AMZN) Counter gives shoppers the option to have their packages delivered via same-day, one-day, two-day or standard shipping to a Rite Aid retail location. “Being the first store partner for Counter in the U.S. is a differentiator for Rite Aid and we believe our partnership with Amazon, that includes Locker, creates a stronger in-store experience for existing customers and new customers that come in to pick up their packages,” said Jocelyn Konrad, executive vice president, Pharmacy and Retail Operations for Rite Aid.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Cemtrex, Inc. (NASDAQ: CETX ) shares were ...
Rite Aid Corporation (RAD) posted its Q1 2020 earnings results on Wednesday, June 26, after market close. This report was disappointing with an adjusted loss of -$0.14 per share, a steep dive from our zacks Consensus Estimate of +$0.02.
Amazon introduced Thursday a new service called Counter, a network of pickup points where consumers can walk into a Rite Aid store to pick up packages delivered to the store. The service is available at more than 100 Rite Aid stores and will expand throughout the rest of the year.
Rite Aid shares moved sharply lower in after-hours trading only to open higher on Thursday following mixed first quarter results.
tumbled in premarket trading on Thursday, though recovered at the opening bell, after the struggling pharmacy chain reported a fiscal first-quarter loss almost double from a year ago amid sluggish sales in its retail pharmacy and prescription segments. Rite Aid stock plunged more than 10% in premarket trading on Thursday after the company reported an adjusted net loss from continuing operations of $7.5 million, or 14 cents a share, compared to adjusted net income of $1 million, or 2 cents a share, a year earlier. Rite Aid said it expects to post a net loss of between $170 million and $220 million, and adjusted per share results of between a 14-cent loss and 72-cent gain on sales of between $21.5 billion and $21.9 billion.